GHRH and benign prostatic hyperplasia: GH-RH and its receptors are expressed in experimental models of BPH, in which antagonists of GH-RH suppressed the levels of proinflammatory cytokines and altered the expression of genes related to epithelial-to-mesenchymal transition (EMT).